Identities, specificities, and use of twenty two (22) differentially expressed protein biomarkers for blood based diagnosis of breast cancer
The present invention discloses twenty two 22 protein biomarkers of breast cancer. More specifically, the present invention discloses the identities, specificities, and uses of up to twenty two (22) protein biomarkers in blood serum for distinguishing between patients with earlier and later stages of breast cancer, patients with benign breast diseases or abnormalities, and normal individuals lacking breast abnormalities.
1 . Twenty two (22) protein biomarkers as related to breast cancer.
2 . A method for screening, diagnosis, or staging of patients with breast cancer, whereby 1, 2, or more of up to the 22 protein biomarkers of claim 1 in human blood identified as related to breast cancer are employed for differentiating between patients having an earlier and/or later stage of breast cancer, patients having a benign breast disease or abnormality, and normal control individuals. The method comprises:
collecting a whole blood, blood serum, or blood plasma sample from a test subject;
determining the concentrations of up to 22 protein biomarkers identified as related to breast cancer in the test subject sample, and
determining the concentrations of up to 22 protein biomarkers identified as related to breast cancer in samples from patients having biopsy confirmed and histological staged breast cancer, patients having a benign breast abnormality or benign breast disease, and normal control individuals having no evidence of breast disease or breast abnormality,
Performing a statistical analysis and determining whether or not the test subject is normal, has benign breast disease or abnormality or has an earlier and/or later stage of breast cancer, based on a statistical analysis of the concentration in blood serum of the one, two or more of the selected 22 protein biomarkers.
3 . The method of claim 2 , wherein the concentration of the protein biomarkers are determined by first separating the proteins by 2D gel electrophoresis.
4 . The method of claim 2 , wherein the statistical analysis is an analysis of variance, a multivariate linear or quadratic discriminant analysis, a multivariate canonical discriminant analysis, a receiver operator characteristics (ROC) analysis, and/or a statistical plot such as a Box and Whiskers plot and/or a receiver operator characteristics (ROC) plot.
5 . One, two or more biomarkers of claim 1 , wherein the biomarker is one, two or more of the following 22 biomarkers:
An inter-alpha-trypsin inhibitor heavy chain (H4) related protein and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
an immunoglobulin lambda chain protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
an alpha-1-microglobulin protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
an Apolipoprotein A-I protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
an Apolipoprotein E protein, an Apolipoprotein E3 protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Complement C4 protein, a Complement C4A protein, a Complement C4A gamma chain protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Serum Albumin protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Lectin P35 protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Transferrin protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Haptoglobin protein, and/or one or more of the biomarker protein isoforms or post-synthetic modification variants of a Haptoglobin protein, and/or a processing product thereof, and/or
an Apoptosis inhibitor expressed by Macrophages (AIM), and/or a Human secreted protein CD5L, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Haptoglobin-related protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants post-synthetic modification variants, and/or processing products thereof, and/or
a Serotransferrin protein and/or a Siderophilin protein and/or a Beta-1-metal-binding globulin protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a nucleolar protein, and/or a ribosomal protein, and/or a 60S ribosomal protein L27a protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
a Reticulon-4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen) (Neuroendocrine-specific protein) (NSP) (Neuroendocrine-specific protein C homolog) (RTN-x) (Reticulon-5) protein, and/or one or more of the biomarker protein isoforms, and/or post-synthetic modification variants, and/or processing products thereof, and/or
one or more of the proteins comprising the amino acid sequences #1-23, referred to in Table VI, and/or depicted as protein spots: B1512; B1418; B1322; B2412; B2505: B3406; B2422; B3410; B3506; B4008; B4206; B4404; B4424; B5539; B5713; B6605; B6519; B6218; B6014; B7408; and/or B7108, in the 2D gels in FIG. 1 and/or FIG. 6 .